Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.09. | AEON Biopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.08. | AEON Biopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
12.08. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.06. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.06. | AEON Biopharma, Inc. - 10-Q/A, Quarterly Report | 1 | SEC Filings | ||
11.06. | AEON Biopharma, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
23.05. | AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 182 | GlobeNewswire (Europe) | IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
20.05. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.05. | AEON Biopharma GAAP EPS of $2.28 | 1 | Seeking Alpha | ||
14.05. | AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | 167 | GlobeNewswire (Europe) | - Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k)... ► Artikel lesen | |
25.04. | NYSE American accepts AEON Biopharma's plan to regain listing | 1 | Seeking Alpha | ||
25.04. | AEON Biopharma erhält Zustimmung der NYSE American für Compliance-Plan | 1 | Investing.com Deutsch | ||
25.04. | AEON Biopharma gets NYSE American nod for compliance plan | 1 | Investing.com | ||
25.04. | AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance | 707 | GlobeNewswire (Europe) | IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
21.04. | AEON Biopharma ernennt Rob Bancroft zum neuen CEO | 2 | Investing.com Deutsch | ||
21.04. | AEON Biopharma names Rob Bancroft as new CEO | 1 | Investing.com | ||
21.04. | AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 133 | GlobeNewswire (Europe) | IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
21.04. | AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer | 731 | GlobeNewswire (Europe) | IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
21.04. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
24.03. | AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | 436 | GlobeNewswire (Europe) | - Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k)... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ALTERITY THERAPEUTICS | 0,005 | 0,00 % | ALTERITY THERAPEUTICS LIMITED: Alterity Presents Positive ATH434 Data at 2025 MDS Congress | ||
BIOCURE TECHNOLOGY | 0,047 | +1,08 % | Biocure Technology Inc (2): Biocure shareholders approve all matters at AGM | ||
RECURSION PHARMACEUTICALS | 6,080 | 0,00 % | What's Going On With Recursion Pharmaceuticals Stock On Wednesday? | ||
QIAGEN | 40,765 | +1,52 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
IMMUNOVANT | 16,075 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
KYMERA THERAPEUTICS | 56,29 | -0,97 % | Stifel bestätigt Kaufempfehlung für Kymera Therapeutics vor wichtigen Studiendaten | ||
ARCUTIS BIOTHERAPEUTICS | 21,240 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 37,485 | -0,44 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
DISC MEDICINE | 70,28 | +3,52 % | Mona Ashiya verlässt Verwaltungsrat von Disc Medicine - Gremium auf acht Mitglieder verkleinert | ||
ARVINAS | 9,750 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
JANUX THERAPEUTICS | 24,200 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
BIONTECH | 91,15 | -0,33 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
AMYLYX PHARMACEUTICALS | 13,480 | -0,15 % | BofA Securities hebt Kursziel für Amylyx-Aktie auf 16 US-Dollar an | ||
STRUCTURE THERAPEUTICS | 28,450 | 0,00 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
LENZ THERAPEUTICS | 48,600 | 0,00 % | Lenz Therapeutics platziert Aktienpaket im Wert von 80 Millionen US-Dollar |